Repare Therapeutics (RPTX) Price & Analysis

Compare

433 Followers

RPTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.89 - $4.07

Previous CloseN/A

Volume283.97K

Average Volume (3M)496.53K

Market Cap

$65.73M

Enterprise Value-$49.16M

Total Cash (Recent Filing)$109.47M

Total Debt (Recent Filing)$649.00K

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Nov 05, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding42,959,170

10 Day Avg. Volume82,840

30 Day Avg. Volume496,529

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.75

Enterprise Value/Revenue-0.92

Enterprise Value/Gross Profit-1.27

Enterprise Value/Ebitda0.44

Forecast

1Y Price Target

$1.50

Price Target Upside-3.23% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company has a cash runway guidance through 2027, supported by $109.5 million in cash, equivalents, and marketable securities.

Monetization StrategyRepare announced entry into a worldwide, exclusive license agreement with Debiopharm around lunreserb, yielding $10M upfront and up to $257M in potential milestones.

Strategic PartnershipsRepare Therapeutics Inc announced an agreement with DCx Biotherapeutics to outlicense their preclinical discovery engines in exchange for $4M cash and other incentives.

Bears Say

Clinical Trial LimitationsThe upcoming clinical trial results are based on a small and heterogeneous patient set, making it unlikely to lead to a 'proof-of-concept type of conclusion.'

Net LossRepare reported a Q1 net loss of $30MM.

Operational ChallengesA previous 75% workforce reduction was approved by the board, indicating potential operational or financial challenges.

Repare Therapeutics News

Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year

Reports Q2 revenue $250,000, consensus $1.67M. “We remain focused on exploring strategic alternatives and partnerships across our portfolio...

16d ago

RPTX

Repare Therapeutics: Strategic Partnerships and Cautious Optimism Amid Uncertain Trial Outcomes Justify Hold Rating

LifeSci Capital analyst Charles Zhu has maintained their neutral stance on RPTX stock, giving a Hold rating on...

13d ago

RPTX

Repare Therapeutics Reports Q2 2025 Results and Strategic Moves

Repare Therapeutics Inc ( ($RPTX) ) has released its Q2 earnings. Here is a breakdown of the information...

15d ago

RPTX

Repare Therapeutics Announces Licensing Deal and Strategic Updates

An update from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics has entered a worldwide licensing...

15d ago

RPTX

Repare Therapeutics Signs Licensing Deal with Debiopharm

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. On July 15, 2025, Repare Therapeutics entered...

1M ago

RPTX

Closing Bell Movers: Victory Capital gains on S&P 400 inclusion

In the opening 90 minutes of the evening session, U.S. equity futures are down slightly with a 0.2%...

1M ago

BHF

BLK

Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib

Repare Therapeutics (RPTX) announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A., a...

1M ago

RPTX

Repare Therapeutics Updates Severance Benefits for Executives

Repare Therapeutics ( ($RPTX) ) has issued an announcement. On June 13, 2025, Repare Therapeutics Inc.’s Compensation Committee...

2M ago

RPTX

Repare Therapeutics Holds Annual Shareholder Meeting

Repare Therapeutics ( ($RPTX) ) has shared an announcement. On June 17, 2025, Repare Therapeutics held its Annual...

2M ago

RPTX

Repare Therapeutics Strengthens Leadership with New Executive Appointment

Repare Therapeutics ( ($RPTX) ) just unveiled an update. Repare Therapeutics Inc. has announced an amendment to its...

3M ago

RPTX

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates

Repare Therapeutics ( ($RPTX) ) has shared an announcement. Repare Therapeutics has announced a strategic partnership with DCx...

3M ago

RPTX

Repare Therapeutics reports Q1 EPS (71c) vs 30c last year

“During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via...

3M ago

RPTX

Repare Therapeutics expects cash to fund operations through 2027

Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were...

3M ago

RPTX

RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Repare Therapeutics Inc (RPTX) is scheduled to report 1st quarter earnings on 05/13/2025. Regarding Q1 estimates, Wall Street...

3M ago

RPTX

RPTX FAQ

What was Repare Therapeutics Inc’s price range in the past 12 months?

Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.07 in the past 12 months.

What is Repare Therapeutics Inc’s market cap?

Repare Therapeutics Inc’s market cap is $65.73M.

When is Repare Therapeutics Inc’s upcoming earnings report date?

Repare Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 73 days.

How were Repare Therapeutics Inc’s earnings last quarter?

Repare Therapeutics Inc released its earnings results on Aug 08, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.559 by $0.169.

Is Repare Therapeutics Inc overvalued?

According to Wall Street analysts Repare Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Repare Therapeutics Inc pay dividends?

Repare Therapeutics Inc does not currently pay dividends.

What is Repare Therapeutics Inc’s EPS estimate?

Repare Therapeutics Inc’s EPS estimate is -0.12.

How many shares outstanding does Repare Therapeutics Inc have?

Repare Therapeutics Inc has 42,959,170 shares outstanding.

What happened to Repare Therapeutics Inc’s price movement after its last earnings report?

Repare Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.559. Following the earnings report the stock price went up 1.316%.

Which hedge fund is a major shareholder of Repare Therapeutics Inc?

Currently, no hedge funds are holding shares in RPTX

Repare Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-69.96%

Trailing 12-Months

Asset Growth

-44.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Repare Therapeutics Inc

Repare Therapeutics (RPTX) is a leading clinical-stage precision oncology company focused on developing novel therapeutics for cancer treatment. Leveraging its proprietary synthetic lethality approach, Repare Therapeutics utilizes CRISPR-enabled, genome-wide synthetic lethality screens to discover and develop innovative therapies that target specific genetic vulnerabilities in cancer cells. The company's pipeline includes several promising drug candidates aimed at addressing unmet medical needs in oncology.

Repare Therapeutics (RPTX) Earnings & Revenues

Historic Earnings Reports

RPTX Stock 12 Month Forecast

Average Price Target

$1.50

▼(-3.23% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,1.5,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >